onc Videos

Videos

Muhammad Danyal Ahsan, New York Presbyterian Hospital, Weill Cornell Medicine

Videos

Mutational Landscape of Homologous Recombination Deficiency Pathogenic Gene Variants in Colorectal Cancer

08/18/2023

At the 2023 World Congress on Gastrointestinal Cancers, Muhammad Danyal Ahsan discusses results from a study that utilized the GENIE database to determine the potential utility of widespread functional HRD status assessment in colorectal...

At the 2023 World Congress on...

08/18/2023

Oncology

Giovanni Randon, MD, Fondazione IRCCS Istituto Nazionale dei Tumori

Videos

Relationship Between Clinicopathological Features and Immunotherapy Benefit Among Patients With dMMR/MSI-High Metastatic or Unresectable Gastric Cancer

08/17/2023

Giovanni Randon , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Giovanni Randon, MD, presented results from a study relating clinicopathological features and immunotherapy benefit among patients with dMMR/MSI-high metastatic or unresectable gastric...

At the 2023 World Congress on...

08/17/2023

Oncology

Videos

Future Potential of Noncovalent BTK Inhibitor Therapy for Patients With Chronic Lymphocytic Leukemia

08/17/2023

Susan M. O'Brien , MD;

Susan M. O'Brien, MD, discusses the possible applications of pirtobrutinib, a noncovalent BTK inhibitor, for the treatment of patients with CLL.

Susan M. O'Brien, MD, discusses...

08/17/2023

Oncology

Videos

Promising Prognostic Value of Diagnosis to Treatment Interval Among Patients With Newly Diagnosed Mantle Cell Lymphoma

08/17/2023

Narendranath Epperla , MD, MS;

Narendranath Epperla, MD, MS, shares findings assessing the potential significance of DTI for predicting outcomes for patients with newly diagnosed MCL.

Narendranath Epperla, MD, MS,...

08/17/2023

Oncology

Videos

Optimal Frontline Treatment Regimens for Patients With Chronic Lymphocytic Leukemia

08/16/2023

Susan M. O'Brien , MD;

At the 2023 EHA meeting in Frankfurt, Germany, Susan M. O'Brien, MD, provided insights into the latest frontline therapeutic options for patients with chronic lymphocytic leukemia.

At the 2023 EHA meeting in...

08/16/2023

Oncology

Gerald Prager, MD, Medical University of Vienna

Videos

Trifluridine/Tipiracil Plus Bevacizumab For Refractory Metastatic Colorectal Cancer

08/11/2023

Gerald Prager , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Gerald Prager, MD, presents data on a trial evaluating trifluridine/tipiracil plus bevacizumab for patients with refractory metastatic colorectal cancer.

At the 2023 World Congress on...

08/11/2023

Oncology

Videos

Addition of Trastuzumab to Perioperative Chemotherapy Improved Response Rates Among Patients with HER2-Positive Gastric or Gastroesophageal Junction Cancer

08/11/2023

Anna Dorothea Wagner , PD;

At the 2023 World Congress on Gastrointestinal Cancers, Anna Wagner, MD, discusses the addition of trastuzumab to perioperative chemotherapy for patients with HER2-positive gastric or gastroesophageal junction cancer.

At the 2023 World Congress on...

08/11/2023

Oncology

Zev Wainberg, MD, University of California - Los Angeles

Videos

NALIRIFOX Regimen As First-Line Therapy for Patients With Metastatic Pancreatic Ductal Adenocarcinoma

08/10/2023

Zev Wainberg , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Zev Wainberg, MD, presents data from the NAPOLI 3 study, evaluating NALIRIFOX in the first-line setting for patients with metastatic pancreatic ductal adenocarcinoma.

At the 2023 World Congress on...

08/10/2023

Oncology

Akihito Kawazoe, MD, National Cancer Center East - Japan

Videos

Lenvatinib Plus Pembrolizumab Did Not Significantly Improve Survival Among Patients with Metastatic Colorectal Cancer

08/10/2023

Akihito Kawazoe , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Akihito Kawazoe, MD, shared results from the phase 3 LEAP-017 trial, evaluating lenvatinib plus pembrolizumab among previously treated patients with metastatic colorectal cancer.

At the 2023 World Congress on...

08/10/2023

Oncology

Andrea Bullock, MD, Harvard Medical School

Videos

Botensilimab-Balstilimab Showed Durable Responses for Metastatic Microsatellite Stable Colorectal Cancer

08/10/2023

Andrea Bullock , MD;

At the 2023 World Congress on Gastrointestinal Cancers, Andrea Bullock, MD, discussed the expanded phase 1 trial of bostensilimab plus balstilimab for heavily pretreated, metastatic microsatellite stable colorectal cancer.

At the 2023 World Congress on...

08/10/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology